IL1B and cancer: The research highlights that IL-1B enhances epithelial-to-mesenchymal transition (EMT), invasion, and migration of cancer cells, and its inhibition through IL-1 β antibodies or IL-1R antagonists like Canakinumab and Anakinra reduces metastasis.